Impact Success Stories: Interview with Prof Caitriona O鈥橠riscoll on GENEGUT
, an EU鈥慺unded project coordinated by Prof Caitriona O鈥橠riscoll, aims to develop a first in class oral RNA-based medicine for Crohn鈥檚 disease. In a recent interview with , part of the Horizon Europe support network, she outlined GENEGUT鈥檚 goal and impact.
GENEGUT aims to deliver RNA directly to the site of inflammation in the gut using biodegradable nanoparticles. The approach offers a more targeted and less invasive alternative to existing treatments.
Speaking about the wider impact of the research, she said:
The interdisciplinary approach of the GENEGUT project will help to reduce the disease burden for CD patients, increase the quality of life, decrease hospitalisation, decrease work related sick leave, decrease the financial burden for healthcare providers, and improve the quality of healthcare.